{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:16:56Z","timestamp":1792513016627,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.soncn.2023.151545","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T09:42:40Z","timestamp":1700905360000},"page":"151545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Sara","family":"Parreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Moldawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazy","family":"Zomordian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesan","family":"Bandali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Virdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghara","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharanija","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Teresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.soncn.2023.151545_bib0001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, nccn clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.soncn.2023.151545_bib0002","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.soncn.2023.151545_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.soncn.2023.151545_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2020.12.009","article-title":"Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: long-term efficacy and safety from a phase Ib trial","volume":"145","author":"Atkins","year":"2021","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.soncn.2023.151545_bib0005","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.soncn.2023.151545_bib0006","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.soncn.2023.151545_bib0007","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.soncn.2023.151545_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100564","article-title":"Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101","volume":"7","author":"Tomita","year":"2022","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.soncn.2023.151545_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.11329","article-title":"Real-world survival outcomes associated with first-line immunotherapy, targeted therapy, and combination therapy for metastatic clear cell renal cell carcinoma","volume":"4","author":"Chakiryan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.soncn.2023.151545_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.861189","article-title":"Real-world therapy management and outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States","volume":"12","author":"Zakharia","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.soncn.2023.151545_bib0011","article-title":"Comparative effectiveness of front-line ipilimumab and nivolumab or axitinib and pembrolizumab in metastatic clear cell renal cell carcinoma","author":"Zarrabi","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.soncn.2023.151545_bib0012","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2021.12.007","article-title":"Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"37","author":"Bosma","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"17","key":"10.1016\/j.soncn.2023.151545_bib0013","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2023.151545_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejon.2021.102043","article-title":"The role of nursing in the management of patients with renal and hepatic cancers: a systematic literature review","volume":"55","author":"Kelly","year":"2021","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.soncn.2023.151545_bib0015","article-title":"The effectiveness of nurse-led interventions for cancer symptom management 2000\u20132018: a systematic review and meta-analysis","volume":"4","author":"Kelly","year":"2022","journal-title":"Health Sci Rev"},{"key":"10.1016\/j.soncn.2023.151545_bib0016","series-title":"Cancer Medicine 6","article-title":"American Cancer Society","author":"Kufe","year":"2003"},{"issue":"21","key":"10.1016\/j.soncn.2023.151545_bib0017","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1002\/cncr.29585","article-title":"Nursing intervention to enhance outpatient chemotherapy symptom management: patient-reported outcomes of a randomized controlled trial","volume":"121","author":"Traeger","year":"2015","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.soncn.2023.151545_bib0018","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejon.2014.03.006","article-title":"The power of nursing: guiding patients through a journey of uncertainty","volume":"18","author":"Komatsu","year":"2014","journal-title":"Eur J Oncol Nurs"},{"issue":"2","key":"10.1016\/j.soncn.2023.151545_bib0019","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/nop2.664","article-title":"Did we do everything we could have? Nurses' contributions to medicines optimization: a mixed-methods study","volume":"8","author":"Logan","year":"2021","journal-title":"Nurs Open"},{"key":"10.1016\/j.soncn.2023.151545_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.690","article-title":"The role of oncology nurses in treatment-related adverse event management: an international online survey","volume":"32","author":"Fern\u00e1ndez- Ortega","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.soncn.2023.151545_bib0021","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4103\/apjon.apjon_6_19","article-title":"Adverse events of oncologic immunotherapy and their management","volume":"6","author":"Barber","year":"2019","journal-title":"Asia-Pac J Oncol Nursing"},{"issue":"1","key":"10.1016\/j.soncn.2023.151545_bib0022","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.apjon.2021.12.007","article-title":"Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment","volume":"9","author":"Shankar","year":"2022","journal-title":"Asia-Pac J Oncol Nurs"},{"issue":"11","key":"10.1016\/j.soncn.2023.151545_bib0023","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.soncn.2023.151545_bib0024","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.soncn.2023.151545_bib0025","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.soncn.2023.151545_bib0026","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.soncn.2023.151545_bib0027","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41416-020-0949-9","article-title":"Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events","volume":"123","author":"Grunwald","year":"2020","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.soncn.2023.151545_bib0028","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2021.04.042","article-title":"The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care","volume":"80","author":"Bedke","year":"2021","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.soncn.2023.151545_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.soncn.2023.151545_bib0030","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.soncn.2023.151545_bib0031","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40262-013-0068-3","article-title":"Clinical pharmacology of axitinib","volume":"52","author":"Chen","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.soncn.2023.151545_bib0032","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1016\/j.clgc.2021.03.019","article-title":"Time to resolution of axitinib-related adverse events after treatment interruption in patients with advanced renal cell carcinoma","volume":"19","author":"Rini","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.soncn.2023.151545_bib0033","article-title":"Living alone as a risk factor for cancer incidence, case-fatality and all-cause mortality: a nationwide registry study","volume":"15","author":"Elovainio","year":"2021","journal-title":"SSM Popul Health"},{"issue":"6","key":"10.1016\/j.soncn.2023.151545_bib0034","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1188\/14.CJON.637-640","article-title":"Chemotherapy education for patients with cancer: a literature review","volume":"18","author":"Valenti","year":"2014","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2023.151545_bib0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/2277-9531.171782","article-title":"Effect of self-care education on the quality of life in patients with breast cancer","volume":"4","author":"Shahsavari","year":"2015","journal-title":"J Educ Health Promot"},{"issue":"5","key":"10.1016\/j.soncn.2023.151545_bib0036","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1188\/14.CJON.18-05AP","article-title":"The effects of education on anxiety levels in patients receiving chemotherapy for the first time: an integrative review","volume":"18","author":"Garcia","year":"2014","journal-title":"Clin J Oncol Nurs"},{"issue":"3","key":"10.1016\/j.soncn.2023.151545_bib0037","first-page":"271","article-title":"Immune checkpoint inhibitor therapy: key principles when educating patients","volume":"23","author":"Wood","year":"2019","journal-title":"Clin J Oncol Nurs"},{"issue":"5","key":"10.1016\/j.soncn.2023.151545_bib0038","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/NCC.0000000000000521","article-title":"Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma","volume":"41","author":"Brunot","year":"2018","journal-title":"Cancer Nurs"},{"issue":"8","key":"10.1016\/j.soncn.2023.151545_bib0039","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.soncn.2023.151545_bib0040","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2016.6749","article-title":"Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials","volume":"3","author":"Basch","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2_suppl","key":"10.1016\/j.soncn.2023.151545_bib0041","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/JOP.19.00647","article-title":"Toxicity management of front-line pembrolizumab combined with axitinib in clear cell metastatic renal cell carcinoma: a case study approach","volume":"16","author":"Wood","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.soncn.2023.151545_bib0042","series-title":"Diarrhea","year":"2020"},{"issue":"2","key":"10.1016\/j.soncn.2023.151545_bib0043","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.aogh.2016.02.003","article-title":"Expanding the role of nurses to improve hypertension care and control globally","volume":"82","author":"Himmelfarb","year":"2016","journal-title":"Ann Glob Health"},{"issue":"6","key":"10.1016\/j.soncn.2023.151545_bib0044","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.soncn.2023.151545_bib0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-018-0708-8","article-title":"Tyrosine kinase inhibitor-induced hypertension","volume":"20","author":"Agarwal","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"10.1016\/j.soncn.2023.151545_bib0046","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.2012.44.4216","article-title":"Systematic monitoring and treatment of physical symptoms to alleviate fatigue in patients with advanced cancer: a randomized controlled trial","volume":"31","author":"de Raaf","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.soncn.2023.151545_bib0047","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.6004\/jnccn.2015.0122","article-title":"Cancer-Related Fatigue, Version 2.2015","volume":"13","author":"Berger","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 1","key":"10.1016\/j.soncn.2023.151545_bib0048","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.3747\/co.2008.171","article-title":"Chemotherapy-and cancer-related nausea and vomiting","volume":"15","author":"Warr","year":"2008","journal-title":"Curr Oncol"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208123002206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208123002206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:41:18Z","timestamp":1760082078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208123002206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0749208123002206"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2023.151545","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2023.151545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151545"}}